The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“validates ...

Shares of Glenmark Pharmaceuticals Ltd on Friday jumped 10 per cent after the firm said it has signed a deal with AbbVie to commmercialise its underdevelopment drug aimed to treat cancer and ...

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

The Europe Pharmaceutical Drugs Market size is valued at USD 450 billion in 2025 and is expected to reach USD 610 billion by ...

The funding will be deployed over a three-year period from 2025 to 2027, enabling Alfasigma to significantly advance its R&D ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile compared to linezolid, with potential to replace this current cornerstone in ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

Across our campus and throughout our nearly 400 years, Harvard innovation—in medicine, technology, education, and beyond—has ...

This article investigates pharmaceutical innovation by analysing data on the companies that introduced the ∼1,200 new drugs that have been approved by the US FDA since 1950. Implications of this ...

Antibody-drug conjugates (ADCs) represent a mechanistically defined class of targeted therapeutics that combine monoclonal antibodies with cytotoxic payloads to achieve selective delivery to ...

However, the relationship between prices (and revenues) and new drug approvals is uncertain, and there are significant limitations with the existing policy analysis. This short executive summary ...